Cogent Biosciences (COGT) saw a 126.3% surge in stock price after positive clinical trial results for their stomach cancer treatment. The combination of bezuclastinib and sunitinib showed significant improvement in patient outcomes. COGT plans to raise $200 million for further development and commercialization of their drug candidates. The CEO expressed optimism that their treatment could become the new standard of care. While COGT shows promise, some believe AI stocks offer better returns with lower risk. For more stock insights, check out reports on stocks expected to double in 3 years and hidden AI stocks.

Read more at Yahoo Finance: Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress